Cybin, trading under the ticker CYBN, has been granted a U.S. patent, numbered 12,318,477, by the United States Patent and Trademark Office. This patent supports Cybin's CYB004 deuterated DMT initiative, which is being developed as a potential treatment for generalized anxiety disorder.
The patent covers unique formulations of DMT and its deuterated isotopologues specifically for intramuscular administration, including CYB004. This newly granted patent is expected to offer market exclusivity until the year 2040.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Cybin Inc (CYBN, Financial) is $71.28 with a high estimate of $151.12 and a low estimate of $25.19. The average target implies an upside of 779.97% from the current price of $8.10. More detailed estimate data can be found on the Cybin Inc (CYBN) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Cybin Inc's (CYBN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
